Lexaria Bioscience (LEXX) Accounts Payables (2011 - 2026)

Lexaria Bioscience has disclosed Accounts Payables across 16 years of filings, most recently posting $182611.0 for Q1 2026.

• Accounts Payables for Q1 2026 came in at $182611.0, down 89.82% year-over-year; the trailing twelve-month figure through Feb 2026 was $182611.0 (down 89.82% YoY), and the FY2025 annual result was $1.5 million, up 37.19% from the prior year.
• Accounts Payables came in at $182611.0 for Q1 2026 at Lexaria Bioscience, down from $1.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.8 million in Q1 2025 to a low of $55318.0 in Q1 2024.
• The 5-year median for Accounts Payables is $239941.0 (2023), against an average of $591837.0.
• Across the five-year window, Accounts Payables surged 3141.4% in 2025 and sank 89.82% in 2026, its largest moves.
• Lexaria Bioscience's Accounts Payables stood at $241891.0 in 2022, then tumbled by 59.09% to $98969.0 in 2023, then soared by 171.79% to $268986.0 in 2024, then surged by 429.93% to $1.4 million in 2025, then sank by 87.19% to $182611.0 in 2026.
• The last three Accounts Payables figures came in at $182611.0 (Q1 2026), $1.4 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.